INmune Bio reports press release available

INmune Bio, Inc.

INmune Bio, Inc.

INMB

0.00
  • INmune Bio disclosed completion of a commercial manufacturing milestone for its CORDStrom platform, supporting planned global registration filings.
  • First commercial-ready umbilical cord tissue was processed at the UK Cell and Gene Therapy Catapult under an agreement with Anthony Nolan.
  • Manufacturing is positioned to support a planned Phase 3 confirmation trial for Ebstrocel in RDEB, targeting US, EU, UK submissions.
  • Update cited alignment with the MHRA draft rare disease therapies regulatory framework; consultation link: https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200700PRIMZONEFULLFEED9764091) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.